Industry News
Scientific discovery may stop breast cancer spreading to the bones
5/28/2015
Researchers have discovered a protein that drives the spread of breast cancer to the bone, bringing them a step closer to finding a way to prevent secondary breast cancer.
Researchers developing new targeted and immune therapies for colorectal cancer molecular subtypes
5/28/2015
Medical oncology is a rapidly evolving field, and oncology-related precision medicine - or the matching of treatments to a specific patient and their cancer - is at the forefront of this evolution.
Genelux Corporation, a clinical-stage biopharmaceutical company focused on the development of vaccinia virus for oncolytic immunotherapy, today announced that data from two Phase I trials...
Entolimod may be a promising treatment option for many solid tumors
5/28/2015
A collaborative team of researchers led by Alex A. Adjei, MD, PhD, FACP, of Roswell Park Cancer Institute (RPCI) will share results from the first clinical study of the anticancer effects of the...
UMN research identifies potential proteins to target in osteosarcoma treatment
5/28/2015
New genetic mouse model allows for comprehensive analysis of drivers for osteosarcomaNew models developed at the Masonic Cancer Center, University of Minnesota reveal the genes and pathways that...
Machine-learning breakthrough paves way for medical screening, prevention and treatment
5/28/2015
A breakthrough in machine learning has also brought about a "game changer" for the science of metabolomics - and will hasten the development of diagnostic and predictive tests for Alzheimer's...
Pinpointing natural cancer drug's true origins brings sustainable production a step closer
5/28/2015
For decades, scientists have known that ET-743, a compound extracted from a marine invertebrate called a mangrove tunicate, can kill cancer cells.
Prostate cancer is the second most common type of cancer in men and is predicted to result in an estimated 220,00 cases in the United States in 2015.
Promising trial of brigatinib shows all next-gen ALK inhibitors may not be created equal
5/28/2015
Phase I/II clinical trial results reported at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show promising results for investigational drug brigatinib against ALK+ non-small...
Tumor surroundings are shown to affect progression of different cancer subtypes
5/28/2015
Treatments may need to be tailored not just to specific cancer types but also to factors distinguishing environments in which they developOur environment can have a major impact on how we...